Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir

Journal of Viral Hepatitis

Volumn 7, Issue 2, 2000, Pages 161-165

  Ying, C ^a   De Clercq, E ^a   Nicholson, W ^b   Furman, P ^b   Neyts, J ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Triangle Pharmaceuticals   (United States)

Author keywords

Adefovir; DAPD; HBV; L FMAU; Lamivudine; Penciclovir; Tenofovir

Indexed keywords

1BETA 2,6 DIAMINOPURINE DIOXALANE; ADEFOVIR; CLEVUDINE; COMPLEMENTARY DNA; DNA POLYMERASE; LAMIVUDINE; LOBUCAVIR; METHIONINE; NUCLEOSIDE DERIVATIVE; PENCICLOVIR; RNA; TENOFOVIR; TETRACYCLINE; UNCLASSIFIED DRUG; VALINE; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG POTENCY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; VIRUS REPLICATION;

ACYCLOVIR; ADENINE; ANTIVIRAL AGENTS; ARABINOFURANOSYLCYTOSINE TRIPHOSPHATE; CELL LINE; DIOXOLANES; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; GUANINE; HEPATITIS B VIRUS; HUMANS; ORGANOPHOSPHORUS COMPOUNDS; PHOSPHONIC ACIDS; PURINE NUCLEOSIDES; VIRUS REPLICATION;

EID: 0034108712     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2000.00210.x     Document Type: Article

References (32)

1. 1 Ganem D. Hepadnaviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM et al., eds. Fields Virology. 3rd edn. Philadelphia: Lippincott-Raven Publishers, 1996: 2703-2737.
2. 2 Hoofnagle JH. Therapy of viral hepatitis. Digestion 1998; 59: 563-578.
3. 3 Jarvis B, Faulds D. Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 1999; 58: 101-141.
4. 4 Niesters HGM, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus ADME. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177: 1382-1385.
5. 5 Bartholomeusz A, Locarnini S. Mutations in the hepatitis B virus DNA polymerase gene that are associated with resistance to famiclovir and lamivudine. Int Antiviral News 1997; 5: 123-124.
6. 6 Ling R. Harrison TJ. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 1999; 80: 601-606.
7. 7 Pillay D, Bartholomeusz A, Cane P, Mutimer D, Schinazi RF, Locarnini S. Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance. Int Antiviral News 1998; 6: 167-169.
8. 8 Shaw T, Locarnini SA. Preclinical aspects of lamivudine and famciclovir against hepatitis B virus. J Viral Hepat 1999; 6: 89-106.
9. 9 Seifer M, Hamatake RK, Colonno RJ, Standring DN. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chemother 1998; 42: 3200-3208.
10. 10 Dunkle LM. Lobucavir: new broad-spectrum antiviral agent. In: Sapienza DM, ed. Antivirals, Latest Preclinical and Clinical Developments for Infectious Diseases, Southborough, MA: Intern Business Communications, Inc., 1998: 1-4.
11. 11 Chen H, Manouilov KK, Chu CK, Schinazi RF, McClure HM, Boudinot FD. High-performance liquid Chromatographic determination of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane, and their metabolite (-)-beta-D-dioxolane guanine in monkey serum, urine and cerebrospinal fluid. J Chromatogr B Biomed Sci Appl 1997; 691: 425-432.
12. 12 Manouilov KK, Manouilova LS, Boudinot FD, Schinazi RF, Chu CK. Biotransformation and pharmacokinetics of prodrug 9-(beta-i)-l,5-dioxolan-4-yl)-2-aminopurine and its antiviral metabolite 9-(beta-D-l,3-dioxolan-4-yl) guanine in mice. Antiviral Res 1997; 35: 187-193.
13. 13 Chu CK, Ma T, Shanmuganathan K et al. Use of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39: 979-981.
14. 14 Balakrishna-Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother 1996; 40: 380-386.
15. 15 Liu SH, Grove KL, Cheng YC. Unique metabolism of a novel antiviral L-nucleoside analog, 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil: a substrate for both thymidine kinase and deoxycytidine kinase. Antimicrob Agents Chemother 1998; 42; 833-839.
16. 16 Aguesse-Germon S, Liu SH, Chevallier M et al. Inhibitory effect of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil on duck hepatitis B virus replication. Antimicrob Agents Chemother 1998; 42: 369-376.
17. 17 Chu CK, Boudinot FD, Peek SF et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. In: Schinazi RF, Sommadossi J-P. Thomas HC, eds. Therapies for Viral Hepatitis. London: International Medical Press, 1998: 303-312.
18. 18 Tennant BC, Jacob J. Graham LA, Peek S, Du J, Chu CK. Pharmacokinetic and pharmacodynamic studies of 1-(2-fluoro-5-methyl-β-L-arabinofuranosyl) uracil (L-FMAU) in the woodchuck model of hepatitis B virus infection. Antiviral Res 1997; 34 (abstr 36).
19. 19 De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, Maudgal PC. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986; 323: 464-467.
20. 20 De Clercq E. Sakuma T, Baba M et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res 1987; 8: 261-272.
21. 21 Heijtink RA, De Wilde GA, Kruining J et al. Inhibitory effect of 9-(2-phosphonylmethoxyethyl) adenine (PMEA) on human and duck hepatitis B virus infection. Antiviral Res 1993; 21: 141-153.
22. 22 Gilson RJ, Chopra K, Murray-Lyon I et al. Adefovir dipivoxil (Bis-POM PMEA) treatment for chronic hepatitis B infec-tion: a placebo-controlled phase I/II study. 36th Annual Meeting of the American Society for Microbiology. New Orleans, Louisiana, September 15-18. Late Breakers 1996: 7 (no. LB1).
23. 23 Jeffers L, Heathcote E, Wright T et al. A phase II dose-ranging, placebo-controlled trial of adefovir dipivoxil for the treatment of chronic hepatitis B virus infection. Abstracts of the Eleventh International Conference on Antiviral Research. San Diego, California, April 5-10. Late Breakers 1998: 9 (no. 197).
24. 24 Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 1998; 28: 1669-1673.
25. 25 Perrillo R, Schiff E, Magill A, Murray A. Jn vivo demonstration of sensitivity of YMDD variants to adefovir. Abstracts of the 34th Annual Meeting of the European Association for the Study of the Liver (EASL). Naples, Italy, 8-12 April 1999.
26. 26 Tarantal AF, Marthas ML, Shaw JP, Cundy K, Bischofberger N. Administration of 9-[2-(R)-(phosphonomethoxy) propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immun Defic Syndr Hum Retrovirol 1999; 20: 323-333.
27. 27 Deeks SG, Barditch-Crovo P, Lietman PS et al. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy) propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998; 42: 2380-2384.
28. 28 Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: a review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997; 8: 1-23.
29. 29 Ladner SK, Otto MJ, Barker CS et al. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 1997; 41: 1715-1720.
30. 30 Ying C. Van Pelt J, Yap SH, De Clercq E. Neyts J. Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation. J Virol Methods 1999; 81: 155-158.
31. 31 Ladner SK, Miller TJ, Otto MJ. King RW. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues. Antiviral Chem Chemother 1998; 9: 65-72.
32. 32 Ladner SK, Miller TJ, King RW. The M5 39V polymerase variant of human hepatitis B virus demonstrates resistance to 2′deoxy-3′-thiacytidine and a reduced ability to synthesize viral DNA. Antimicrob Agents Chemother 1998; 42: 2128-2131.